Kelan tietotarjotinSiirry sisältöön

Decreasing Trend in the Use and Long-Term Use of Benzodiazepines Among Young Adults

Julkaistu 1.5.2018

Tiivistelmä

Objective

Patterns of benzodiazepine (BZD) use and long-term use among young adults are not well known. Our aim was to study trends in BZD use and long-term use among 18-25-year-old young adults by gender and active substance in a nationwide retrospective longitudinal register-based setting.

Methods

All Finns aged 18-25 years with reimbursed purchases of BZDs in 2006-2014 recorded to the Finnish Prescription Register were included. Annual prevalence rates of BZD use and long-term use among young adults were reported overall, according to gender, drug group (anxiolytic or hypnotic), and active substance. Long-term use of BZDs was defined as purchasing ≥180 Defined Daily Doses (DDDs) in at least two drug purchases during a calendar year.

Results

Overall prevalence of BZD use among young adults decreased from 24.0 to 18.8 users per 1000 inhabitants in 2006-2014. Prevalence of long-term use decreased from 5.5 to 3.3 users per 1000 inhabitants. Overall BZD use was higher among females, whereas long-term use was more common among males. Use of anxiolytics was more common than use of hypnotics. Oxazepam, alprazolam, zopiclone, and zolpidem were the most used BZDs, whereas alprazolam and clonazepam were the substances with most long-term use. The use and long-term use of BZDs have decreased annually since 2008 among Finnish young adults. Further research is needed to investigate the reasons behind the decline.

Lue koko artikkeli (liebertpub.com)

Tekijät

Sanna Tähkäpää, Leena K Saastamoinen, Marja Airaksinen, Annamari Tuulio-Henriksson, Terhi Aalto-Setälä, Terhi Kurko

Lisätietoja julkaisusta

  • Vertaisarvioitu: kyllä.
  • Avoin saatavuus: ei.
  • Koko viite: Tähkäpää, S. M., Saastamoinen, L., Airaksinen, M., Tuulio-Henriksson, A., Aalto-Setälä, T., & Kurko, T. (2018). Decreasing Trend in the Use and Long-Term Use of Benzodiazepines Among Young Adults. Journal of child and adolescent psychopharmacology, 28(4), 279–284. https://doi.org/10.1089/cap.2017.0140

Jaa tämä artikkeli

Jaa sivu Twitteriin Jaa sivu Facebookiin Jaa sivu LinkedIniin